Lantheus Holdings (LNTH) said Monday it has agreed to acquire Life Healthcare Group subsidiary Life Molecular Imaging in an all-cash deal worth up to $750 million.
The consideration consists of an upfront payment of $350 million and up to an additional $400 million in potential earn-out and milestone payments. Lantheus Radiopharmaceuticals UK, a unit of Lantheus, may pay up to $30 million toward Life Medical Group's retained future contingent liabilities, subject to certain contract arrangements.
The deal is expected to complete in H2 2025, subject to clearance from regulators and approval from Life Healthcare's shareholders.
Lantheus expects the deal to be accretive to adjusted per-share earnings within 12 months of completion.
The company anticipates that the acquisition will strengthen its growth profile with the addition of Neuraceq, a diagnostic agent to detect beta-amyloid plaques in patients with Alzheimer's Disease.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。